Web Research

Web Research — What the Internet Knows

The Bottom Line from the Web

The single most important thing the internet reveals that the audited filings do not lead with is a Turkish Competition Authority (Rekabet Kurumu) antitrust probe opened 26 February 2026 into 26 banks, insurers and IT firms — AgeSA named alongside Akbank, Garanti, Yapı Kredi, İş Bankası, QNB, HSBC, Aksigorta, Bupa Acıbadem and Katılım Emeklilik — for alleged no-poaching labor-market collusion. The Authority's "serious and sufficient" evidentiary finding does not yet amount to a violation, but the Turkish Competition Board has repeatedly fined labor-market violators in the last five years and has an explicit Guidelines on Labour-Market Infringements (adopted 21 Nov 2024). Everything else the web reveals is directionally bullish on fundamentals but dependent on regulatory catalysts — specifically the Supplementary Pension System (TES), now officially scheduled for Q2 2026 launch with mandatory 2% employer / 3% employee / 1% government contributions, and the CBRT's rate-cut cycle now parked at 37% (March 2026) after five consecutive cuts.

Price (₺)

236.30

P/E (TTM)

7.7

Div Yield (%)

2.94

1-Year Return (%)

76.3

What Matters Most

1. Turkish antitrust probe — active no-poaching investigation (26 Feb 2026)

On 26 February 2026, Turkey's Competition Board opened a full investigation into 26 banking, insurance and IT companies — **AgeSA, Aksigorta, Bupa Acıbadem and Katılım Emeklilik among insurers; Akbank, Garanti, İş Bankası, Yapı Kredi, QNB, HSBC, ING, Denizbank, TEB, Odea, Şekerbank, Albaraka and Kuveyt Türk among banks** — for alleged "no-poaching" agreements and exchange of competitively sensitive labor-market information. The Authority said preliminary-inquiry evidence "raised serious and sufficient concerns." Turkey's Competition Board issued formal Guidelines on Labour-Market Infringements on 21 Nov 2024 and has conducted four labour-market investigations in four years involving 50+ undertakings, with material fines. AgeSA sits inside the Sabancı financial-services grouping (Akbank, Aksigorta, Agesa, Sabancı Ageas Sağlık) — cross-group HR coordination is the probable locus of the probe. Source: Hürriyet Daily News 25 Feb 2026 (https://www.hurriyetdailynews.com/turkish-competition-authority-launches-probe-into-26-companies-219303); Kluwer Competition Blog, 14 Dec 2024.

2. Supplementary Pension System (TES) officially scheduled for Q2 2026 — biggest structural catalyst

The **2026 Presidential Annual Program** (published 30 Oct 2025) confirms the new mandatory Supplementary Retirement System (*Tamamlayıcı Emeklilik Sistemi*, TES) will be launched in **Q2 2026**, converting the voluntary OKS auto-enrolment scheme into a Pillar-II pension system with mandatory contributions: **employer 2.0%, employee 3.0%, government 1.0% of covered pay**. All existing OKS balances migrate automatically to TES. Current OKS rules have no employer contribution and a 30% government top-up on employee contributions — so on a same-wage base, employer + government flows roughly **triple** on migration. For AgeSA (the #1 private BES operator by AuM), this is the single biggest AuM TAM event of the cycle. WTW and HUB International both confirm the same Q2 2026 launch date with identical contribution architecture. Sources: WTW 12/2025 brief, HUB International 25 Nov 2025 bulletin.

3. CBRT rate path: 50% peak in March 2024 → 37% in March 2026 — reinvestment-yield compression

The Central Bank of Turkey has cut its policy rate five consecutive times from the 50% peak (Mar 2024) down to 37% (22 Jan 2026), then held at 37% through the March 2026 meeting as Middle East energy-price shocks pushed the CBRT to pause. Year-end 2025 CPI closed at 30.89% (down from 45% in mid-2024). The CBRT's 2026 policy calendar reaffirms a 5% long-term inflation target. For an insurer that holds ~₺30bn+ of short-duration TRY instruments backing technical reserves, every 100 bp of rate cut compresses reinvestment yield by ~1%, and the historical 90%+ of AgeSA's non-technical "financial income" line is driven by this book. Rate-cut duration is now the single biggest operating assumption. Sources: global-rates.com CBRT repo history, tradingeconomics.com Mar 2026 hold, turkiyetoday.com 5 Jan 2026 inflation print.

4. Dual-CEO key-person risk — Fırat Kuruca runs BOTH AgeSA and Aksigorta since June 2024

On **24 May 2024** Aksigorta's long-serving CEO Uğur Gülen resigned (13 years in the role); AgeSA CEO Fırat Kuruca was appointed acting CEO of Aksigorta effective 1 June 2024 while retaining his AgeSA mandate. On **23 August 2024** Sabancı Holding made this permanent — Kuruca is now CEO of BOTH Agesa (since 2017) AND Aksigorta, as part of "integration work in Sabancı Financial Services Group." External reporting (Bloomberg HT, FintechTime) confirms no succession plan disclosed. A single executive now runs two separately listed Borsa Istanbul insurers plus sits on Sabancı Ageas Sağlık's board. This is material key-person risk that is not flagged in AgeSA's disclosures. Source: bloomberght.com 24 May 2024; fintechtime.com 23 Aug 2024.

5. TAS 29 / IAS 29 inflation accounting remains in force — reported growth is real but the wedge is large

Turkey has been classified as hyperinflationary since 2022; IAS 29 / TAS 29 requires all IFRS financial statements (including insurers) to be restated into purchasing-power-equivalent units. The insurance regulator SEDDK has historically given insurers some latitude on applying TAS 29 for statutory solvency, but IFRS filings carry the monetary-loss line explicitly. Alpha Spread analytics confirm AgeSA books a ~27% "monetary-loss" haircut between management and TAS-29 reporting. If end-2025 CPI prints ~30.9% and FY26 inflation drops below the 20% threshold for two years (CBRT targets 5% long-term), Turkey could exit hyperinflationary status, forcing restated history and removing the monetary-loss drag. KPMG and ForvisMazars both confirm the regime remains in place for 2025/2026. Sources: kpmg.com/tr inflation accounting, forvismazars.com/tr IAS 29, ifrs.org jurisdiction profile.

6. Price action: new all-time high ₺256 (Feb 2026), now ₺236 (17 Apr 2026)

Morningstar lists 52-week range ₺128.60 – ₺256.00; current ₺236.30 (17 Apr 2026). Key catalysts behind the Feb 2026 run-up: (a) ₺6.94/share annual dividend declared 23 Feb 2026, up from ₺1.70 in 2024 — a step-change in payout; (b) FY2025 EPS of ₺30.87 (vs ₺15.95 in 2024, +93.5%) released 16 Feb 2026; (c) sell-side price target raised +10% to ₺297 on 14 Jan 2026. Morningstar quant fair value ₺599 (High uncertainty), SimplyWall.st "50.5% undervalued" with implied fair value ~₺475. The 3-month return to mid-April is +8.8% and the 1-year return is +76.3%. Analyst consensus per SimplyWall.st: 9 analysts, price expected to rise 40.7% (implied fair value ₺332). Source: simplywall.st/stocks/tr/insurance/ibse-agesa, morningstar.com/stocks/xist/agesa/quote.

7. Medisa consolidation / Sabancı Ageas Sağlık health rollup

On 20 December 2024, AgeSA closed the acquisition of the remaining 20% stake in Sabancı Ageas Sağlık Sigorta A.Ş. from Aksigorta (AKGRT) for ₺157.25 million in cash — lifting AgeSA to 100% ownership of the health-insurance subsidiary (now branded Medisa). The Turkish health-insurance market is projected at $3.34bn in 2025 growing to $4.14bn by 2031 (3.6–6.3% CAGR) with Allianz, Acıbadem, Anadolu Sigorta and AXA as incumbent leaders — Medisa is a small-share entrant, and consolidated financials will now reflect its loss-making launch phase as a standalone subsidiary. Sources: MarketScreener M&A filing summary, Mordor Intelligence Turkey Health & Medical Insurance market report, marketreportanalytics.com.

8. Dividend policy step-change — payout jumped from ₺1.70 to ₺6.94/share (Feb 2026)

The **23 February 2026** dividend declaration of **₺6.94/share** (payable 27 Mar 2026) is 4× the prior year's ₺1.70/share. SimplyWall.st confirms "dividend increased to ₺6.94 (Feb 26)." Based on FY2025 EPS of ₺30.87, this is a **~22.5% payout ratio** — up from a ~10.7% ratio in FY2024 — and signals a deliberate capital-return rerating. Combined with the **₺750m / 3-year buyback** program launched April 2023 (575k shares bought at ~₺28.28 average as of H1 2023), management is systematically returning capital despite the hyperinflationary backdrop. Source: simplywall.st recent updates, MarketScreener dividend feed.

9. 2021 re-branding from AvivaSA — why Aviva left Turkey

Ageas announced 23 Feb 2021 it would acquire Aviva's 40% stake in AvivaSA for GBP 122m (₺1.2bn / ~EUR 142m). Aviva's exit was driven by its UK-centric strategic refocus ("core UK, Ireland, Canada" narrative) — not by a view on the Turkish business. Ageas, Sabancı's existing non-life JV partner (Aksigorta), called AvivaSA "the 5th-largest Turkish life insurer and leading private pension provider" serving 2m customers; 2020 AvivaSA net result TL 350m, ROE 36%. Rebranding completed 1 Jul 2021; ticker changed to AGESA on 5 May 2021. Continuity of management, bancassurance plumbing (Akbank) and fund-management infrastructure (Ak Portföy) was preserved. Sources: ageas.com press release 23 Feb 2021; aviva.com/newsroom 2021 releases.

10. Governance: Akbank-dominated board, ~20% free float, Sabancı-captive asset management

AgeSA's board is Akbank/Sabancı/Ageas-dominated: Chair Sabri Hakan Binbaşgil is also Chairman of Akbank; other members include Ben Karel E. Coumans (Ageas, Vice-Chair), Emmanuel Van Grimbergen (Ageas), Karolien Gielen (Ageas), Emre Çift (Akbank), Ecem Nalbantgil (Akbank), Fuat Öksüz (Sabancı Holding), and Fırat Kuruca (CEO). SimplyWall.st flags: "Less than half of directors are independent" and "Management criteria: 1/4 checks passed". All pension funds are managed by Ak Portföy (Ak Asset Management) — a Sabancı affiliate — creating a captive asset-management fee arrangement with no visible arm's-length benchmarking. Ownership: Ageas 40% + Sabancı Holding 40% + ~20% free float. Sources: agesa.com.tr/hakkimizda/kurumsal-yonetim, simplywall.st management tab, akportfoy.com.tr pension funds listing.

Recent News Timeline

No Results

Page / 2 15 of 22 records

What the Specialists Asked

Insider Spotlight

No Results

Background note on Fırat Kuruca. Boğaziçi University (Business Administration); career start 1989 in finance and administration across Turkey and abroad; joined Sabancı Group 2005; CB Insights tags Divan Group and Unilever in his pre-Sabancı history. Appointed Agesa CEO 2017-01-01; added Aksigorta acting-CEO role 1 June 2024; made permanent 23 August 2024. This is the single most concentrated key-person risk in the Sabancı financial-services stack — a single executive now runs two separately listed Borsa Istanbul insurers (AgeSA and Aksigorta) plus sits on Sabancı Ageas Sağlık's board. No public succession plan is disclosed.

Board composition highlight. 8 board members: 3 Ageas-affiliated (Coumans, Van Grimbergen, Gielen), 3 Akbank/Sabancı-affiliated (Binbaşgil, Çift, Nalbantgil, Öksüz — actually 4), and CEO Kuruca. SimplyWall.st flags less than half are independent — consistent with a controlled JV.

Absence of Form 4-style insider buying/selling. KAP (Kamuyu Aydınlatma Platformu) searches for directors/executives across 2024-2026 returned no material share purchases or disposals. Given Ageas and Sabancı hold 40% each as strategic shareholders, "insider" trading at the AGESA level is structurally rare. This removes the insider-selling red flag that typically dominates BIST small/mid-cap.

Industry Context

Turkish life & pension sector — 2026 backdrop

Three structural forces matter for AGESA's next 12–24 months:

1. TES launch (Q2 2026). Mandatory 2% employer / 3% employee / 1% government contributions replace the voluntary OKS. Existing OKS balances auto-migrate. This roughly triples the employer + government contribution stream on a same-wage base and is the biggest TAM event in Turkish private pensions since OKS in 2017.

2. CBRT rate cycle. Policy rate at 37% (Mar 2026), down from 50% (Mar 2024). Short-duration TRY reinvestment yields compress roughly in parallel. AgeSA's financial income line — historically the largest non-technical profit driver — mechanically decompresses over 2026–2027 even if underwriting holds.

3. Hyperinflation accounting regime. TAS 29 (=IAS 29) remains in force for 2025 and 2026 financials. End-2025 CPI printed 30.89%; CBRT targets 5% long-term. If inflation stays below ~20% for two years, Turkey could exit hyperinflationary status, forcing restated history — potentially flattering or hurting reported growth depending on the monetary-loss line direction.

Peer positioning

No Results

BIST-100 and lira context

The Turkish lira REER weakened to 71.11 (CPI-based) by May 2025 per ainvest.com Aug 2025 analysis. USD/TRY settled near 44.85 in April 2026. BIST-100 trades around 14,588 (17 Apr 2026). In hyperinflationary Turkey, TRY-quoted equity returns must be adjusted for CPI to derive real returns — AGESA's +76.3% 1-year TRY return against ~31% CPI implies ~35% real return, which is materially above the BIST-100 real return in the same window (BIST broadly tracks CPI). Sources: en.wikipedia.org/wiki/BIST_100, ainvest.com Aug 2025 REER analysis, turkiyetoday.com Jan 2026 CPI print.

Health-insurance market (relevant for Medisa)

Turkish health-insurance market: $3.34bn in 2025 → projected $4.14bn by 2031 (3.6% CAGR) per Mordor Intelligence; alternative forecast 6.3% CAGR to 2033 per marketreportanalytics.com. Key players: Allianz Türkiye, ACIBADEM Health Group, Anadolu Insurance, AXA Türkiye. Medisa (100%-owned since Dec 2024) is a small-share entrant and is the principal ROE drag on consolidated financials during its loss-making launch phase. Sources: mordorintelligence.com Turkey health & medical insurance; insightmarketreports.com.